$QRXPY to file NDA within two months -

QRxPharma to file NDA within two months - U.S. Food and Drug Administration, QRxPharma, clinical trials - Australian Life Scientist:

"QRxPharma (ASX: QRX) is nearing the final hurdle in bringing its dual-opioid pain drug, MoxDuo, to market, with the company planning to file a New Drug Application (NDA) with the US Food and Drug Administration within the next two months.

MoxDuo IR capsules are a patented 3:2 fixed ratio combination of morphine and oxycodone that targets the acute pain market, a $2.5 billion segment of the $7 billion spent annually on prescription opioids in the US."